EUDAMED Vigilance Module: Mandatory Use Postponed to No Earlier Than 2028

EVERBIZ | Original compilation. Please credit the source when republishing.

EUDAMED Vigilance Module: Mandatory Use Postponed to No Earlier Than 2028

In one sentence

On 22 October 2026, the European Commission informed stakeholders that mandatory use of the EUDAMED Vigilance and Post-Market Surveillance module (the “vigilance module”) will not start before 2028. The previous official roadmap had expected Q2 2027.

The reason is that the first functional audit of the vigilance module identified issues that must be fixed before a second audit. Until then, manufacturers continue to report incidents and recalls in the EU through the existing channels of the national competent authorities.

Mind the wording: Media headlines say “postponed to 2028”, but the Commission’s own wording is “no earlier than 2028”. This is an earliest date, not a fixed date, and it may still change.

Background: EUDAMED and the vigilance module

EUDAMED is the EU database on medical devices. It consists of six modules that are being rolled out in stages:

Module What it covers Mandatory use
Actor registration Manufacturers, authorised representatives and importers obtain an SRN From 28 May 2026
UDI/device registration Registration of device and UDI data From 28 May 2026
Notified bodies and certificates CE certificate information From 28 May 2026
Market surveillance Surveillance information exchanged between national competent authorities From 28 May 2026
Vigilance and post-market surveillance Post-market reports such as serious incidents and recalls No earlier than 2028
Clinical investigations/performance studies Applications and reports for clinical investigations Not yet mandatory; not covered by this news

The “post-market module” refers to the fifth row. Don’t confuse it with the fourth, “market surveillance”, which is used by the authorities and is already mandatory.

Once the vigilance module is in use, manufacturers will mainly submit:

  • Serious incident reports (MIR), commonly known as adverse event reports;
  • Field safety corrective actions (FSCA) and field safety notices (FSN), e.g. recalls or software update notices;
  • Trend reports and periodic summary reports;
  • Periodic safety update reports (PSUR) for certain higher-risk devices.

In short: the first four modules cover “register before placing on the market”, while the vigilance module covers “how to report when something goes wrong after placing on the market”.

EUDAMED Vigilance Module: Mandatory Use Postponed to No Earlier Than 2028

Why the delay?

According to reports, the postponement came about as follows:

  1. A first functional audit of the vigilance module was carried out and identified issues. The Commission has not specified what they were.
  2. The Commission needs to add functionality and fix defects. Testing with national competent authorities, originally planned for Q3 2026, has been moved to early 2027.
  3. After the fixes, a second functional audit is required. Work in 2027 will mainly focus on resolving the issues from the first audit and additional testing.
  4. Only after the second audit is passed can a notice be published in the Official Journal; mandatory use starts six months after publication. This puts the earliest date in 2028.

The system is postponed, not the obligation

This is the point most easily misread: only the requirement to submit “via EUDAMED” is postponed. The vigilance reporting obligation itself remains fully in force, and the reporting deadlines have not been relaxed.

Situation Reporting deadline under MDR Article 87
Serious incident (general) No later than 15 days after becoming aware
Death or unanticipated serious deterioration in state of health No later than 10 days after becoming aware
Serious public health threat No later than 2 days after becoming aware

Until the vigilance module becomes mandatory, the practice stays the same:

  • Use the harmonised EU MIR form and report to the competent authority of the Member State where the incident occurred;
  • FSCAs and FSNs are likewise reported to the relevant national competent authorities;
  • Each country accepts reports differently – some by e-mail, some via their own national portal.

For manufacturers outside the EU, these reports are usually submitted and coordinated with the help of the EU authorised representative.

A knock-on effect: simplified registration of legacy devices is also delayed

Some devices were withdrawn from the market before the MDR/IVDR applied but may still be in use in hospitals or by patients. If an incident occurs with such a device, it must still be reported.

Under the EU arrangements, once the vigilance module becomes mandatory, manufacturers of such devices must complete a simplified registration in EUDAMED specifically for vigilance reporting. With the vigilance module delayed, this simplified registration is postponed as well.

If you have devices that were exported to the EU years ago and are no longer sold, no action is needed yet – but we recommend compiling a list of these devices and their current use now.

By the way: the US adverse event system is also running late

According to reports, FDA’s plan to replace the MAUDE database with its new Adverse Event Monitoring System (AEMS) is also behind schedule:

  • When FDA announced the plan in March 2026, it expected the replacement to be completed by May 2026;
  • AEMS was deployed on 27 July 2026 to collect electronic medical device reports (eMDR);
  • However, the public can still only search via MAUDE, with data delayed by about one month.

MAUDE is also linked to FDA’s product classification database and the Total Product Life Cycle (TPLC) database, so it is unclear whether it can be fully retired. For companies, MAUDE remains the tool for searching competitors’ adverse event records.

What does this mean for manufacturers?

  1. More time to prepare – but no holiday. The existing national reporting channels will remain in use for more than another year. Vigilance procedures don’t need to be rewritten for EUDAMED yet, but the procedures themselves must work.
  2. The four mandatory modules are unaffected. Actor registration and device/UDI registration have been hard requirements since 28 May 2026. The vigilance module will draw on this data later – accurate entries now mean smoother reporting later.
  3. Companies selling in several Member States still face “one channel per country”. If your products are sold in several Member States, you need to know how each national competent authority accepts reports.
  4. Clarify the division of tasks with your authorised representative. Who assesses whether an event is a serious incident, who completes the MIR, and who communicates with the authorities should be aligned in the EU AR mandate and the vigilance procedure.

Three things we recommend doing now:

  • Check that the reporting deadlines, MIR form version and national contact details in your vigilance procedure are up to date;
  • Verify the actor and device data already registered in EUDAMED;
  • Watch for the Commission’s further announcements in 2027 – the final date is the one published in the Official Journal of the EU.

EVERBIZ continuously tracks global medical device regulatory developments. If you have questions about EU authorised representation, EUDAMED registration or vigilance reporting, please contact us.

Scroll to Top